Loading clinical trials...
Loading clinical trials...
An Open-Label Phase 1b QT/QTc Study of JNJ-56021927 (ARN-509) in Subjects With Castration-Resistant Prostate Cancer
Conditions
Interventions
Apalutamide
Locations
5
United States
Greenville, South Carolina, United States
Montreal, Quebec, Canada
Chisinau, Moldova
Rotterdam, Netherlands
Sutton, United Kingdom
Start Date
December 18, 2015
Primary Completion Date
September 20, 2016
Completion Date
October 13, 2022
Last Updated
November 9, 2023
NCT06844383
NCT05919264
NCT06615752
NCT06334120
NCT06190899
NCT07005154
Lead Sponsor
Aragon Pharmaceuticals, Inc.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions